A staggering 800% increase in licensing agreement deal values for messenger ribonucleic acid (mRNA)-based innovator ...

Strategic Collaboration to Address Critical Healthcare Needs and Expand Access to Life-Changing Treatments ...

Eli Lilly (NYSE: LLY) plans to invest $206M to expand its Suzhou, China site for Type 2 diabetes and obesity drugs. The ...

Report Ocean, a leading strategic consulting and market research firm, in its recent study, estimated the Global Pharmaceutical Excipients Market size at USD 8.89 billion in 2023. During the forecast ...

and has been granted a new cultivation license by Health Canada. Production is expected to begin in early 2025, marking ...

Inventive deal structures are on the rise within China’s life sciences industry, with the “NewCo” model having garnered significant interest ...

India’s pharmaceutical industry is projected to hit $42.9b by 2028 with a compound annual growth rate of 6.3% in local ...

Mubadala Investment Company has empowered its new specialty pharmaceutical business, KELIX Bio, to acquire a 100 per cent ...

The draft amendment to the Law on Pharmacy plays a crucial role in promoting innovation and modernisation of the Vietnamese ...

GSK and CureVac restructured their 2020 collaboration into a new licensing agreement worth up to $1.57 billion in July 2024.

AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion ...